When starting a new clinical study and preparing the data collection design, you may ask yourself: How important is Controlled Terminology (CT)? How do I prepare the data collection process to be CDISC compliant and avoid rework for submissions? We often receive questions such as these. Whether you are newer to clinical studies or a seasoned veteran, CT can often be an elusive and confusing topic. Having a better understanding of CT standards and requirements, as well as CT-related issues found in validation checks, can improve your submission data and processes.
Pinnacle 21’s Sarah Angelo recently hosted a webinar to provide some insight into and best practices for Controlled Terminology. She received almost two hundred questions, so this blog post serves as a follow-up with the key responses. For the full webinar, you can watch the video recording above and download the slide deck.
Studies that obtain results for multiple types of lab tests have not only numerous records, but also an extensive list of units associated with the results. So, one of the most popular questions asked at the webinar was in regard to changing a Lab unit synonym value to display the CDISC submission value. As stated in the SDTMIG, the variable LBORRESU uses the UNIT codelist. This means that sponsors should submit a term from the column "CDISC Submission Value" in the published Controlled Terminology List maintained for CDISC by NCI EVS.
If sponsors have units that are not in the CDISC Submission Value column, check if the provided unit is mathematically synonymous with an existing unit and submit lab values using that unit. For example: "g/L" and "mg/mL" are mathematically synonymous. However, only "g/L" is in the CDISC UNIT codelist. If this is not the case, and no synonymous unit applies, then submit a New-Term Request Form.
To sum it up:
Although CT requirements have become more universal, the FDA and PDMA have separate Controlled Terminology requirements listed in their respective Technical Conformance Guides (TCG). It’s important to recognize the differences not only between FDA and PMDA, but also among the new, ongoing, and pooled studies. Below is a quick rundown of the guidance from each agency.
New Studies
Ongoing Studies
Pooled Studies
Links to TCGs
FDA: https://www.fda.gov/media/136460/download
PMDA: https://www.pmda.go.jp/files/000229468.pdfhttps://www.pmda.go.jp/files/000229468.pdf
The FDA TCG discourages the creation of custom terms (i.e., so-called extensible code lists) for a submission, because this does not support semantically interoperable study data exchange. Furthermore, the use of custom or extensible code lists does not imply that sponsors may substitute their own nonstandard terms in place of existing equivalent standardized terms.
For example: If "Informed Consent Withdrawn" is collected on the CRF as a disposition event, which is associated with Extensible codelist (NCOMPLT), it is recommended to map to the corresponding CDISC term "WITHDRAWAL BY SUBJECT".
CT2002 – Fix Tips
If we missed any burning questions or topics, check out the full webinar and slide deck to see if we covered it. If you still have other questions, please feel free to contact us!
Tags:
Blog Main Page